Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Living Donor Liver Transplantation
The A2ALL LADR Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Living Donor Liver Transplantation (sub-study to main A2ALL study)
The purpose of this study is to learn if pre-liver transplant treatment using peginterferon plus ribavirin will clear HCV RNA from the blood in HCV-infected recipients, and reduce the risk of recurrent HCV and re-infection of the new liver with hepatitis following liver transplant.
Patients awaiting deceased donor liver transplant will be asked to enroll in this protocol at the time of identification of a potential living liver donor. This study involves about nine centers in the United States and will be enrolling 150 patients in this study over a four-year period.
- Adult (18 years of age or older)
- LDLT candidate
- HCV RNA positive
- Expected time on treatment is at least 12 weeks
IRB Project Number:
Patrice Al-Saden, RN